182 related articles for article (PubMed ID: 8070026)
1. Preclinical and phase I trials of topoisomerase I inhibitors.
Von Hoff DD; Burris HA; Eckardt J; Rothenberg M; Fields SM; Chen SF; Kuhn JG
Cancer Chemother Pharmacol; 1994; 34 Suppl():S41-5. PubMed ID: 8070026
[TBL] [Abstract][Full Text] [Related]
2. [Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan].
Bonneterre J
Bull Cancer; 1995 Aug; 82(8):623-8. PubMed ID: 7492818
[TBL] [Abstract][Full Text] [Related]
3. Camptothecin analogues: studies from the Johns Hopkins Oncology Center.
Slichenmyer WJ; Rowinsky EK; Grochow LB; Kaufmann SH; Donehower RC
Cancer Chemother Pharmacol; 1994; 34 Suppl():S53-7. PubMed ID: 7520844
[TBL] [Abstract][Full Text] [Related]
4. Clinical trials with the topoisomerase I inhibitors.
Burris HA; Rothenberg ML; Kuhn JG; Von Hoff DD
Semin Oncol; 1992 Dec; 19(6):663-9. PubMed ID: 1334279
[TBL] [Abstract][Full Text] [Related]
5. Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro.
Eckardt JR; Burris HA; Kuhn JG; Bissery MC; Klink-Alakl M; Clark GM; Von Hoff DD
J Natl Cancer Inst; 1994 Jan; 86(1):30-3. PubMed ID: 8271279
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients.
Abigerges D; Armand JP; Chabot GG; Bruno R; Bissery MC; Bayssas M; Klink-Alakl M; Clavel M; Catimel G
Anticancer Drugs; 1996 Feb; 7(2):166-74. PubMed ID: 8740721
[TBL] [Abstract][Full Text] [Related]
7. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro.
Burris HA; Hanauske AR; Johnson RK; Marshall MH; Kuhn JG; Hilsenbeck SG; Von Hoff DD
J Natl Cancer Inst; 1992 Dec; 84(23):1816-20. PubMed ID: 1331485
[TBL] [Abstract][Full Text] [Related]
8. 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
Saijo N; Nishio K; Kubota N; Kanzawa F; Shinkai T; Karato A; Sasaki Y; Eguchi K; Tamura T; Ohe Y
Cancer Chemother Pharmacol; 1994; 34 Suppl():S112-7. PubMed ID: 8070019
[TBL] [Abstract][Full Text] [Related]
9. [Topoisomerase inhibitors developing in Japan].
Furue H
Gan To Kagaku Ryoho; 1993 Jan; 20(1):42-9. PubMed ID: 8422186
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Mathijssen RH; Loos WJ; Verweij J; Sparreboom A
Curr Cancer Drug Targets; 2002 Jun; 2(2):103-23. PubMed ID: 12188913
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
[TBL] [Abstract][Full Text] [Related]
12. Clinical, pharmacokinetic and biological studies of topotecan.
O'Dwyer PJ; LaCreta FP; Haas NB; Halbherr T; Frucht H; Goosenberg E; Yao KS
Cancer Chemother Pharmacol; 1994; 34 Suppl():S46-52. PubMed ID: 8070027
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
Gerrits CJ; de Jonge MJ; Schellens JH; Stoter G; Verweij J
Br J Cancer; 1997; 76(7):952-62. PubMed ID: 9328159
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase I inhibitors in the treatment of colorectal cancer.
Rothenberg ML; Blanke CD
Semin Oncol; 1999 Dec; 26(6):632-9. PubMed ID: 10606256
[TBL] [Abstract][Full Text] [Related]
15. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
Philippart P; Harper L; Chaboteaux C; Decaestecker C; Bronckart Y; Gordover L; Lesueur-Ginot L; Malonne H; Lavergne O; Bigg DC; da Costa PM; Kiss R
Clin Cancer Res; 2000 Apr; 6(4):1557-62. PubMed ID: 10778989
[TBL] [Abstract][Full Text] [Related]
16. Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor.
Teicher BA; Holden SA; Khandakar V; Herman TS
J Cancer Res Clin Oncol; 1993; 119(11):645-51. PubMed ID: 8394365
[TBL] [Abstract][Full Text] [Related]
17. Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines.
Jonsson E; Dhar S; Jonsson B; Nygren P; Graf W; Larsson R
Eur J Cancer; 2000 Oct; 36(16):2120-7. PubMed ID: 11044651
[TBL] [Abstract][Full Text] [Related]
18. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
Poddevin B; Riou JF; Lavelle F; Pommier Y
Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
[TBL] [Abstract][Full Text] [Related]
19. Interaction of ionizing radiation with topotecan in two human tumor cell lines.
Marchesini R; Colombo A; Caserini C; Perego P; Supino R; Capranico G; Tronconi M; Zunino F
Int J Cancer; 1996 May; 66(3):342-6. PubMed ID: 8621255
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
Burris HA; Fields SM
Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]